Lion's Mane Extract

Why brands use Lion's Mane Extract

Lion's Mane Extract is a botanical extract reviewed against the target market’s botanical rules, sitting in the botanicals family. On DAT Supply briefs the positioning is set by the brand brief and reviewed against the target market’s claim rules — we do not pre-position an active for any single benefit. Editorial framing uses only EU 432/2012- or DSHEA-compatible wording — we never promote unauthorised claims, even when the active has consumer-side momentum. Format-wise we have considered Lion's Mane Extract for gummies, powder stick and pet soft chew; the per-format formulation notes below describe the live constraints (taste, payload, stability, packaging) we tune in the formulation pass. Sourcing form (extract ratio for botanicals, salt or chelate form for minerals, free-form vs ester for amino acids) is reviewed against the brief, with documentation matched to the target market’s import rules. Inclusion rate and claim wording are reviewed per project — we don’t publish off-the-shelf doses.

How we use Lion's Mane Extract in formulas

A public-safe formulation reference — how this active behaves in our formats, common pairings and handling notes. Final formulation, dose and on-pack copy are confirmed per project.

Heat stable

Limited — use coated forms

Soluble in matrix

Conditional

Vegan supply

Project-specific

EU-authorised health claims

EU-authorised wording for this ingredient is reviewed per project against Reg. 1924/2006 and the authorised list under Reg. 432/2012. No final claim wording is implied by this page.

Botanical actives like Lion's Mane Extract sit in a partially-harmonised EU claims position: most botanical health claims remain on hold (the "on-hold list"), and country-level rules (Italy, France, Spain, Belgium) layer on top with their own positive and negative lists for botanical use. Novel-food status is checked before any brief moves forward, alongside any traditional-use route where it applies. UK rules track EU wording post-Brexit but the GB market follows its own retained list. For the US market, structure-function wording under DSHEA applies, with the FDA disclosure on pack. Pack copy is rewritten per market and reviewed per project.